Clinical trials: Neuropathy, Diabetic
Diabetic Foot Ulcer (DFU), Ulcer Foot
Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs
The purpose of this study is to evaluate the efficacy of four dehydrated complete human placental membrane, also defined as Cellular, Acellular, Matrix-like Products/skin substitutes, plus SOC versus SOC alone in achieving…
- Conditions
- Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
- Trial name
- CAMPSTIM (NCT06449638)
- Testing
- Standard of Care, Revita, Relese
- Where
- 5 sites in United States
- Volunteers
- 272 people
- Sponsor
- StimLabs
Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
- Trial name
- NCT06628908
- Testing
- Suzetrigine, Pregabalin
- Where
- 76 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Diabetic Foot Ulcers
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.
- Trial name
- NCT00563394
- Testing
- ofloxacin, MSI-78
- Where
- United States
- Volunteers
- 584 people
- Sponsor
- Abeona Therapeutics, Inc
Diabetic Foot Ulcer
Assessment of the Efficacy and Safety of a New Medical Device in the Local Treatment of Diabetic Foot Ulcers
Evaluation of the efficacy and safety of a device with LU3103209 compound versus the same device, free of LU3103209 compound, in the local management of DFUs.
- Trial name
- DISCOVERY (NCT03110796)
- Testing
- Dressing with LU3103209 - Dose 1, Dressing with LU3103209 - Dose 2, Dressing without LU3103209
- Where
- 6 sites in Czechia, France and 4 more
- Volunteers
- 210 people
- Sponsor
- Laboratoires URGO
Diabetic Neuropathy, Painful
A Study in Painful Diabetic Neuropathy
This study will investigate the efficacy of a combination treatment of duloxetine + pregabalin compared with the maximal dose of each drug in monotherapy, in patients with diabetic peripheral neuropathic pain (DPNP) who have not…
- Trial name
- COMBO-DN (NCT01089556)
- Testing
- Duloxetine, Pregabalin
- Where
- 54 sites in Australia, Canada and 14 more
- Volunteers
- 811 people
- Sponsor
- Eli Lilly and Company
Foot Ulcer, Diabetic
APT001 Plasma/NO Generator to Treat Diabetic Foot Ulcer in Adults
This is a 10-week, randomized, controlled study to evaluate the efficacy and safety of the APT001 plasma and nitric oxide treatment in subjects with a diabetic foot ulcer.
- Trial name
- APT-14-002 (NCT02356835)
- Testing
- APT001
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Origin Inc.
Diabetic Neuropathy, Painful
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if…
- Trial name
- NCT00159679
- Testing
- Pregabalin
- Where
- 30 sites in United States
- Volunteers
- 167 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Foot Ulcers
Evaluate the Safety and Efficacy of RegenKit Autologous PRP Gel for the Treatment of Diabetic Foot Ulcer
Autologous platelet-rich plasma (PRP) gel was reported to have very good outcomes in the treatment of foot ulcers in pilot studies and retrospective uncontrolled trials.
- Trial name
- NCT02402374
- Testing
- Autologous platelet rich plasma gel
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- Regen Lab SA
Diabetic Foot
The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure
The purpose of the study is to analyse skin blood flow in diabetic patients. The patients receive a single dose of placebo, 1 mg BAY1193397, and 5 mg BAY1193397.
- Trial name
- NCT03128320
- Testing
- BAY1193397
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Bayer
Diabetic Peripheral Neuropathy
Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy
To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain experienced in diabetic peripheral neuropathy (DPN) as measured by changes in PI-NRS after three weeks of treatment compared to the baseline…
- Trial name
- NCT01893125
- Testing
- CNV2197944
- Where
- Hungary
- Volunteers
- 126 people
- Sponsor
- Convergence Pharmaceuticals
Chronic Wounds, Burns
THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers
Pilot observational clinical evaluation assessing the safety and potential effectiveness of THERAVEX Tissue Care Spray Plus as an adjunctive topical therapy for the management of cutaneous wounds, burns, traumatic lesions…
- Conditions
- Chronic Wounds, Burns, Pressure Ulcer, Traumatic Wounds
- Trial name
- NCT07617961
- Testing
- THERAVEX TISSUE CARE SPRAY PLUS
- Where
- Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Biointelligent Technology Systems SL
Diabetic Neuropathy, Painful
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy and safety of intramuscular administration of Engensis on pain in participants with painful diabetic peripheral neuropathy in the feet and lower legs, as compared to Placebo…
- Trial name
- REGAiN-1A (NCT04469270)
- Testing
- Engensis
- Where
- 16 sites in United States
- Volunteers
- 162 people
- Sponsor
- Helixmith Co., Ltd.
Diabetic Neuropathy, Chemotherapy Induced Neuropathy
A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy
A clinical outcomes study measuring reduction in pain and numbness experienced in four types of peripheral neuropathy patients during 60 day administration of the an amino acid formulation.
- Conditions
- Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
- Trial name
- Neuron012703 (NCT01537705)
- Testing
- Neuron012703 (Medical Food)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Targeted Medical Pharma
Diabetic Neuropathies
Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy
The purpose of this study is to determine the safety of TAK-128, once daily (QD), for treatment of diabetic peripheral neuropathy
- Trial name
- NCT00756041
- Testing
- TAK-128
- Volunteers
- 221 people
- Sponsor
- Takeda
Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs)
Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care
This clinical study is being conducted to evaluate how well the Miro3D Wound Matrix helps heal difficult wounds and ulcerations in an outpatient care setting.
- Conditions
- Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs), Pressure Ulcers, Surgical Wound Dehiscence (SWD)
- Trial name
- NCT06939673
- Testing
- Acellular Porcine-Derived Wound Matrix
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Reprise Biomedical, Inc.
Diabetic Foot Ulcers (DFUs), Diabetic Foot
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
This study is designed to evaluate whether the Miro3D Wound Matrix, when used in addition to standard of care, improves healing outcomes in patients with chronic diabetic foot ulcers.
- Conditions
- Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
- Trial name
- FOCUS 3D (NCT07632001)
- Testing
- Miro3D Wound Matrix, Standard of Care
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Reprise Biomedical, Inc.
Neuropathic Foot Ulcer, Foot Ulcer
Vaporous Hyperoxia Therapy (VHT) in the Treatment of Foot Wounds
The purpose of this study is to evaluate the effectiveness of Vaporous Hyperoxia Therapy (VHT), previously named Misty (WTS-1000) for the treatment of chronic foot ulcers.
- Trial name
- VHT1 (NCT04244201)
- Testing
- Vaporous Hyperoxia Therapy
- Volunteers
- 31 people
- Sponsor
- Vaporox
Diabetic Neuropathic Pain
A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain
People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.
- Trial name
- NCT01345045
- Testing
- ABT-639, pregabalin
- Where
- 35 sites in United States, Czechia and 3 more
- Volunteers
- 193 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Painful Diabetic Neuropathy
Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy
The purpose of this study is to determine whether ARC-4558 is effective in managing pain associated with painful diabetic neuropathy.
- Trial name
- NCT00695565
- Testing
- Clonidine Topical Gel (ARC-4558)
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- Arcion Therapeutics Inc
Depressive Disorder, Major, Diabetic Neuropathies
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects.
- Conditions
- Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms
- Trial name
- NCT00456898
- Testing
- desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer